Home / News / Hatchtech receives FDA special protocol agreement of DeOvo™ phase III studies and strengthens patent portfolio

Hatchtech receives FDA special protocol agreement of DeOvo™ phase III studies and strengthens patent portfolio

12 December 2013

Posted in — Media Release

Share

Learn More

Share

You may also like

21 February 2024

Australian engineer invents first artificial heart

News

Bivacor team

29 November 2023

US FDA Grants the BiVACOR Total Artificial Heart IDE Approval for First-in-Human Early Feasibility Study

Media Release

Bivacor team

18 June 2023

Vaxxas opens world-class manufacturing facility to produce needle-free vaccine patch

News, Announcement

30 March 2023

OneVentures pumps up artificial heart group BiVACOR

News, The Australian Financial Review

View All

Ventured. Gained.

Subscribe to our Newsletter.

Name
This field is for validation purposes and should be left unchanged.
decor